biostudies-literatureChen WNational Key R&amp;D Program of ChinaNational Key R&D Program of ChinaBeijing Friendship Hospital377https://www.ebi.ac.uk/biostudies/studies/S-EPMC11515399biostudies-literatureUnknown24(1)<h4>Background</h4>Inflammatory bowel disease (IBD) is a chronic, relapsing condition wherein biologics have improved disease prognosis but introduced elevated infection susceptibility. Vedolizumab (VDZ) demonstrates unique safety advantages; however, a comprehensive systematic comparison regarding the risk of Clostridioides difficile infection (CDI) between vedolizumab and alternative medications remains absent.<h4>Method</h4>Medline, Embase, Cochrane, and clinicaltrials.gov registry were comprehensively searched. Pooled estimates of CDI proportion, incidence, pooled risk ratio between ulcerative colitis (UC) and Crohn's disease (CD), vedolizumab and other medications were calculated. Data synthesis was completed in R using the package "meta".<h4>Results</h4>Of the 338 studies initially iBMC gastroenterologyRisk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.PMC11515399YYZZ2022152023YFC2507300Liu YZong YZhang YZhang HChen WChen CZhou YZhu SZhao HfalseRisk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.<h4>Background</h4>Inflammatory bowel disease (IBD) is a chronic, relapsing condition wherein biologics have improved disease prognosis but introduced elevated infection susceptibility. Vedolizumab (VDZ) demonstrates unique safety advantages; however, a comprehensive systematic comparison regarding the risk of Clostridioides difficile infection (CDI) between vedolizumab and alternative medications remains absent.<h4>Method</h4>Medline, Embase, Cochrane, and clinicaltrials.gov registry were comprehensively searched. Pooled estimates of CDI proportion, incidence, pooled risk ratio between ulcerative colitis (UC) and Crohn's disease (CD), vedolizumab and other medications were calculated. Data synthesis was completed in R using the package "meta".<h4>Results</h4>Of the 338 studies initially i2024-01-01T00:00:00Z2024 Oct2026-07-15T14:52:10.962Z2026-07-06T03:09:09.459ZS-EPMC115153993944896310.1186/s12876-024-03460-z